Rani Therapeutics Stock (NASDAQ:RANI)
Previous Close
$1.21
52W Range
$1.03 - $7.88
50D Avg
$1.45
200D Avg
$2.11
Market Cap
$66.10M
Avg Vol (3M)
$847.17K
Beta
0.24
Div Yield
-
RANI Company Profile
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
RANI Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PHVS | Pharvaris N.V. |
| MOLN | Molecular Partners AG |
| SRZN | Surrozen, Inc. |
| EYPT | EyePoint Pharmaceuticals, Inc. |
| VIRX | Viracta Therapeutics, Inc. |
| ALXO | ALX Oncology Holdings Inc. |
| TNYA | Tenaya Therapeutics, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CABA | Cabaletta Bio, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| TARA | Protara Therapeutics, Inc. |
| BMEA | Biomea Fusion, Inc. |
| TYRA | Tyra Biosciences, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| CRVS | Corvus Pharmaceuticals, Inc. |
| VINC | Vincerx Pharma, Inc. |
| TRVI | Trevi Therapeutics, Inc. |